Cortisone Injections and Joint Injections

Cortisone injections and broader joint injection therapies represent a core non-surgical intervention in orthopedic practice, used to manage pain and inflammation in joints, tendons, and surrounding soft tissues. This page covers the definition and classification of injection types, the physiological mechanism behind corticosteroid and other agents, the conditions most commonly treated, and the clinical boundaries that govern appropriate use. Understanding these boundaries matters because injections carry both therapeutic value and documented risk profiles that inform shared decision-making between patients and orthopedic providers.

Definition and scope

Joint injections are minimally invasive procedures in which a therapeutic agent is delivered directly into a joint space, bursa, tendon sheath, or periarticular tissue using a needle — typically under ultrasound or fluoroscopic guidance to confirm accurate placement. Corticosteroids are the most frequently administered agent class, but the category of joint injections also includes hyaluronic acid (viscosupplementation), platelet-rich plasma (PRP), local anesthetics used in isolation for diagnostic purposes, and emerging biologic agents.

Cortisone is a shorthand term encompassing synthetic corticosteroids such as triamcinolone acetonide, methylprednisolone acetate, betamethasone, and dexamethasone. These compounds differ in their duration of action, solubility, and potency. Triamcinolone acetonide, for example, is a relatively insoluble depot formulation that releases the active agent gradually over days to weeks at the injection site.

The American Academy of Orthopaedic Surgeons (AAOS) publishes clinical practice guidelines that address joint injection protocols, including evidence grading for specific indications. The procedure falls under regulatory-context-for-orthopedics frameworks that govern scope of practice, facility requirements, and informed consent obligations under state medical practice acts and Centers for Medicare & Medicaid Services (CMS) billing rules.

Joint injections are classified within the CPT (Current Procedural Terminology) coding system maintained by the American Medical Association (AMA). Distinct CPT codes differentiate injection by joint size — small (e.g., finger), intermediate (e.g., wrist), and major (e.g., knee, hip, shoulder) — and by guidance method.

How it works

Corticosteroids exert their therapeutic effect primarily through inhibition of phospholipase A2, an enzyme involved in the arachidonic acid cascade that produces prostaglandins and leukotrienes — the principal chemical mediators of inflammation. By blocking this pathway locally, the injected steroid reduces swelling, heat, and pain within the target compartment without the systemic exposure associated with oral corticosteroid courses.

The sequence of events following a corticosteroid injection proceeds in discrete phases:

1. Immediate anesthetic effect — many formulations are combined with lidocaine or bupivacaine, producing pain relief within minutes that lasts 2–6 hours.
2. Onset of steroid effect — anti-inflammatory action typically begins within 24–72 hours as the steroid depot begins releasing the active molecule.
3. Peak effect — most patients experience maximal relief between 1 and 2 weeks post-injection.
4. Duration — therapeutic benefit ranges from 4 weeks to 3 months depending on the agent, the joint injected, and the underlying pathology.
5. Resolution or re-evaluation — if relief is partial or short-lived, the clinical team reassesses the diagnosis and considers alternative interventions.

Hyaluronic acid injections operate through a different mechanism: viscosupplementation introduces a high-molecular-weight lubricant into the joint space, theoretically restoring the viscoelastic properties of degraded synovial fluid. The AAOS has issued a conditional recommendation against viscosupplementation for knee osteoarthritis based on its 2021 clinical practice guideline update, citing insufficient evidence of clinically meaningful benefit over placebo in randomized controlled trial data.

Ultrasound guidance, when used, has been shown in peer-reviewed literature (including studies published in the Journal of Bone and Joint Surgery) to improve needle placement accuracy compared to landmark-guided techniques, particularly in deep or complex joints such as the hip.

Common scenarios

Cortisone and joint injections appear across a broad diagnostic spectrum within orthopedics. The conditions most frequently addressed include:

• Knee osteoarthritis — corticosteroid injection is widely used for acute flares when synovitis is present, as addressed in the broader discussion of osteoarthritis management.
• Rotator cuff tendinitis and subacromial bursitis — subacromial space injections reduce bursal inflammation and allow engagement with physical therapy rehabilitation.
• Trochanteric bursitis — peritrochanteric injections are a first-line non-surgical option when conservative measures fail.
• Trigger finger (stenosing tenosynovitis) — injection into the tendon sheath at the A1 pulley has a reported success rate of approximately 50–70% for single injections, with repeat injection increasing cumulative resolution rates.
• Carpal tunnel syndrome — corticosteroid injection into the carpal tunnel offers temporary symptom relief and is often used diagnostically or as a bridge to surgical planning.
• De Quervain's tenosynovitis — first dorsal compartment injection demonstrates high efficacy for this thumb-side wrist condition.
• Adhesive capsulitis (frozen shoulder) — intra-articular steroid injection combined with physical therapy is a standard early-stage intervention.

The homepage at orthopedicsauthority.com provides a broader orientation to orthopedic care categories, of which injection therapy is one component under the non-surgical pathway.

Decision boundaries

Not all patients with joint pain are candidates for cortisone injection. Clinical decision-making involves a structured evaluation of contraindications, frequency limits, and diagnostic certainty.

Absolute contraindications recognized across orthopedic practice guidelines include:

• Active joint or periarticular infection (septic arthritis)
• Overlying skin infection or cellulitis at the injection site
• Documented allergy to the specific corticosteroid or local anesthetic agent
• Prosthetic joint when infection risk is unacceptably elevated without appropriate antibiotic prophylaxis protocols

Relative contraindications requiring individualized risk-benefit assessment include:

• Poorly controlled diabetes mellitus — corticosteroids reliably elevate blood glucose for 24–72 hours post-injection, and patients with hemoglobin A1c above 9.0% require glucose monitoring protocols
• Anticoagulant therapy — international normalized ratio (INR) thresholds for safe injection vary by joint depth and technique
• Immunosuppression — elevated infection risk alters the risk calculation
• Recent joint injection within the same site — most orthopedic guidelines limit injections to 3–4 per year per joint, with a minimum 6–8 week interval between administrations, based on preclinical evidence of cartilage matrix degradation with frequent high-dose exposure

The AAOS and the American College of Rheumatology (ACR) each publish guidance documents addressing steroid injection frequency. The ACR's 2020 Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee conditionally recommends intra-articular steroid injection for knee osteoarthritis while noting the frequency limitation concern.

Distinguishing cortisone injections from regenerative medicine approaches such as PRP and stem cell therapies is clinically relevant: corticosteroids are anti-inflammatory and catabolic at high doses, whereas PRP delivers growth factors intended to promote tissue repair. These represent mechanistically opposite approaches, and their combined use in the same joint requires careful sequencing to avoid the anti-proliferative effects of steroids neutralizing the regenerative signal.

Image guidance selection also constitutes a decision boundary. Landmark-guided injection remains appropriate for accessible, large joints such as the knee, while hip joint injection without fluoroscopic or ultrasound confirmation carries meaningful risk of intra-articular miss rates reported in cadaveric studies exceeding 25%.

References

• American Academy of Orthopaedic Surgeons (AAOS) — Clinical Practice Guidelines
• American College of Rheumatology — 2020 Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee
• Centers for Medicare & Medicaid Services (CMS) — CPT Coding and Coverage Policy
• American Medical Association — Current Procedural Terminology (CPT)
• National Library of Medicine / PubMed — Journal of Bone and Joint Surgery

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)